Ginkgo Bioworks Holdings, Inc.(DNA) Stock Research - Grey Stern Research
Loading...

Ginkgo Bioworks Holdings, Inc. (DNA) Stock Analysis

$0.81 (-3.98%)

DNA Financial Performance


Use the table below to view Ginkgo Bioworks Holdings, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q4 - 2023

Metric Value Ranking among Peers
Price $0.84 -
52 Week Low $0.72 -
52 Week High $2.55 -
Market Cap $1.9 Billion 1/7
Gross Margin 81% 1/7
Profit Margin -100% 7/7
EBITDA margin -512% 7/7
Q4 - 2023 Revenue $34.8 Million 1/7
Q4 - 2023 Earnings -$211.7 Million 7/7
Q4 - 2023 Free Cash Flow -$61.3 Million 7/7
Trailing 4 Quarters Revenue $251.5 Million 1/7
Trailing 4 Quarters Earnings -$892.9 Million 7/7
Quarterly Earnings Growth -22% 3/7
Annual Earnings Growth 59% 2/7
Quarterly Revenue Growth -65% 7/7
Annual Revenue Growth -15% 7/7
Cash On Hand $944.1 Million 1/7
Short Term Debt $0 4/7
Long Term Debt $221.8 Million 1/7

Ginkgo Bioworks Holdings, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Ginkgo Bioworks Holdings, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 2/7
PS 7.39 1/7
PB 1.69 3/7
PC 1.97 4/7
Liabilities to Equity 0.52 4/7
ROA -0.54 3/7
ROE -0.81 3/7
Current Ratio 2.93 3/7
Quick Ratio 1.66 4/7
Long Term Debt to Equity 0.20 2/7
Debt to Equity 0.20 2/7
Burn Rate 4.28 3/7
Cash to Cap 0.51 4/7
CCR 0.29 6/7
EV to EBITDA -6.37 7/7
EV to Revenue 4.51 1/7

Company Details

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

CEO:

Website: https://www.ginkgobioworks.com

Address: 27 Drydock Avenue Boston, MA

Exchange: New York Stock Exchange

Industry: Biotechnology

Ginkgo Bioworks Holdings, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Ginkgo Bioworks Holdings, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
CohBar, Inc. CWBR $2.6 Million
AVROBIO, Inc. AVRO $62.4 Million
Hepion Pharmaceuticals, Inc. HEPA $7.1 Million
Elevation Oncology, Inc. ELEV $197.2 Million
Ocean Biomedical, Inc. OCEA $61.0 Million
Enveric Biosciences, Inc. ENVB $6.5 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
DNA Income Statements
Quarter Year Revenue Earnings
Q4 2023 $ 34.8 Million -$211.7 Million
Q3 2023 $ 55.4 Million -$302.9 Million
Q2 2023 $ 80.6 Million -$173.3 Million
Q1 2023 $ 80.7 Million -$205.0 Million
Q4 2022 $ 98.3 Million -$174.2 Million
Q3 2022 $ 66.4 Million -$669.1 Million
Q3 2001 $ 66.4 Million -$669.1 Million
Q2 2001 $ 144.6 Million -$670.6 Million

View All

DNA Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q4 2023 $944.1 Million $1.7 Billion $221.8 Million $1.1 Billion
Q3 2023 $1.0 Billion $2.0 Billion $403.7 Million $1.3 Billion
Q2 2023 $1.1 Billion $2.3 Billion $410.9 Million $1.5 Billion
Q1 2023 $1.2 Billion $2.4 Billion $404.1 Million $1.6 Billion
Q4 2022 $1.3 Billion $2.5 Billion $442.6 Million $1.7 Billion
Q3 2022 $1.3 Billion $1.9 Billion $59.8 Million $1.4 Billion
Q2 2022 $1.4 Billion $2.0 Billion $51.5 Million $1.6 Billion
Q4 2001 $1.6 Billion $2.1 Billion $22.3 Million $1.5 Billion

View All

DNA Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q4 2023 -$61.3 Million -$3.4 Million -$101.2 Million
Q3 2023 -$77.9 Million -$4.4 Million -$77.4 Million
Q2 2023 -$87.1 Million -$13.5 Million -$86.6 Million
Q1 2023 -$110.0 Million -$19.4 Million -$110.9 Million
Q4 2022 -$130.3 Million -$25.6 Million $24.1 Million
Q3 2022 -$41.8 Million -$13.5 Million -$75.3 Million
Q3 2001 $572.6 Million $0 $572.6 Million
Q2 2022 -$108.9 Million -$9.6 Million -$115.0 Million

View All